In a NSCLC mouse model, CD38 was found to be upregulated on tumor cells upon resistance to anti-PD-1 axis therapy, which could be reversed with the inhibition of either A2a or CD38 [45]. This evidence concerns the gene CD38 and non-small cell lung carcinoma.